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nanobodies are single-domain antibodies derived from the variable regions of camelidae atypical immunoglobulins. they show promise as high-affinity reagents for research, diagnostics and therapeutics owing to their high specificity, small size (~15 kda) and straightforward bacterial expression. however, identification of repertoires with sufficiently high affinity has proven time consuming and difficult, hampering nanobody implementation. our approach generates large repertoires of readily expressible recombinant nanobodies with high affinities and specificities against a given antigen. We demonstrate the efficacy of this approach through the production of large repertoires of nanobodies against two antigens, GFP and mcherry, with K d values into the subnanomolar range. After mapping diverse epitopes on GFP, we were also able to design ultrahigh-affinity dimeric nanobodies with K d values as low as ~30 pm. the approach presented here is well suited for the routine production of high-affinity capture reagents for various biomedical applications.
There is a continual need in biomedicine for antibodies that recognize target molecules with high affinity and specificity. When high-affinity antibodies are not available for the molecule of interest, common protein tags such as GFP, mCherry and Flag, which do have known antibodies, are invaluable. Most studies demand high-quality antibodies against these protein tags, particularly when affinity isolation is required [1] [2] [3] [4] . Monoclonal or polyclonal antibodies are the primary bait reagents available for these purposes. However, their large size, limited availability and batch-tobatch variation have often proven problematic for biochemical or proteomic studies 5 .
Single-domain antibodies, referred to as nanobodies 6 , have emerged as an alternative to traditional antibodies. Nanobodies are usually derived from camelids such as llamas, which make a unique subset of immunoglobulins consisting of heavy-chain homodimers devoid of light chains [7] [8] [9] ; their variable region (V H H) is the smallest antigen-binding single polypeptide chain found in A robust pipeline for rapid production of versatile nanobody repertoires any natural antibody [8] [9] [10] [11] [12] . Nanobodies are recombinant antigenbinding domains derived from these V H H regions. Unlike monoclonal antibodies, they can readily be produced in large amounts in bacterial expression systems 9, 13 . Moreover, nanobodies are usually extremely stable, can bind antigens with affinities in the nanomolar range and are smaller in size (approximately 15 kDa) than other antibody constructs 11, [14] [15] [16] [17] [18] . However, rapid and robust techniques for isolating extensive repertoires of highaffinity nanobodies have proven elusive: the labor-intensiveness and poor efficiency of current approaches are a major bottleneck for the widespread use of these reagents 8, 12, 14 , explaining why demand for nanobodies greatly exceeds supply 8 .
Here we present a highly optimized pipeline that allows the rapid production of large repertoires of high-affinity nanobodies against selected proteins. The approach is based on high-throughput DNA sequencing of a marrow lymphocyte V H H cDNA library from an immunized llama combined with mass spectrometric (MS) identification of high-affinity V H H regions derived from serum of the same animal. results strategy for nanobody identification Our approach to nanobody discovery centers on MS identification of affinity-purified heavy-chain antibodies isolated from an individual llama, using a DNA sequence database generated from the same animal ( Fig. 1) . This concept is inspired by our previous efforts to identify circulating neutralizing HIV antibodies in humans by MS in conjunction with patient-specific antibody cDNA databases 19 . Our approach represents a pipeline for nanobody production in which each stage has been highly optimized (Supplementary Protocol).
To generate nanobody repertoires of maximal utility, we chose the GFP and mCherry tags as our first target antigens owing to their central roles in cell biological studies. Furthermore, although these fluorescent proteins have broadly similar β-barrel structures, they are evolutionarily divergent and thus are distinct immunogens 20 . After immunization of individual llamas with these antigens and confirmation of an immune response, we serially fractionated serum bleeds to obtain exclusively V H Hcontaining heavy-chain antibodies, taking advantage of the different affinities of protein A and protein G for V H H versus conventional antibodies 7 (Supplementary Fig. 1a ). We affinitypurified the V H H-containing fraction over antigen-coupled resin, washed with MgCl 2 at various stringencies ( Supplementary  Fig. 1b ) and digested with papain on-resin to cleave away the constant regions and leave behind the desired minimal fragments of V H H variable region. Finally, the antigen-bound V H H fragments were eluted and separated by SDS-PAGE, allowing purification of ~15-kDa V H H fragments free from residual conventional Fab fragments and Fc fragments (both ~25 kDa) and undigested antibodies (~50 kDa) ( Supplementary Fig. 1c ). The gel-purified bands were trypsin digested and analyzed by liquid chromatography-MS and tandem MS (MS/MS) ( Fig. 2a) . We recovered the highest-affinity V H H fragments via the highest-stringency washes, which also decreased the complexity of the eluted sample, aiding MS analysis.
To create an animal-specific antibody sequence database, we obtained lymphocyte RNA samples from individual immunized llamas for high-throughput sequencing. We isolated mononuclear cells from bone marrow aspirates, enriching for long-lived antibody-secreting plasma cells, which transcribe elevated levels of immunoglobulin mRNA 19, 21, 22 . Notably, we did not create expression or display libraries, and thus we removed the need for efficient exogenous expression, folding and presentation of the clones.
We generated cDNA from total lymphocyte RNA and performed nested PCR to specifically amplify sequences encoding the V H H variable regions 14 . Sequencing of this PCR product using a high-throughput Roche 454 (GFP) or Illumina MiSeq (mCherry) platform resulted in ~800,000 or ~3,000,000 unique reads, respectively. These reads were translated, filtered and trypsin digested in silico to create a searchable peptide database for MS analysis ( Fig. 1 and Supplementary Fig. 2) .
The identification of specific V H H sequences is more challenging than a typical MS-based protein identification, as they consist in large part of highly conserved framework regions that are less easily distinguished by MS. Moreover, whereas well-established databases are available for other proteins, for V H H a cDNA database must be generated for each immunized animal. To deal with both challenges, we developed a bioinformatic pipeline that identifies the highest-probability matches from a pool of related V H H sequences (Llama Magic; http://www.llamamagic.org/). In this pipeline, V H H sequences are ranked by a metric based on MS sequence coverage of complementarity-determining region 3 (CDR3, the most diverse V H H region) as well as CDR1 and CDR2 coverage, total V H H coverage, sequencing counts, mass spectral counts and the expectation values of matched peptides ( Supplementary Figs. 2  and 3) . Preliminary attempts to identify V H H sequences solely by their CDR3 regions revealed that identical CDR3 sequences are frequently shared between multiple V H H regions that have different CDR1 and CDR2 sequences. This is probably a result of somatic gene conversion, in which, after V(D)J recombination, secondary recombination occurs between upstream V gene segments and already rearranged V(D)J genes 23, 24 .
Our automatic ranking pipeline, coupled with careful manual inspection, overcame these issues and provided 44 highprobability hits for nanobodies against GFP. We classified these as llama antibody against GFP (LaG) 1-44 and subjected them to further screening ( Supplementary Fig. 4 ). In the analysis of llama antibodies against mCherry (LaM), a smaller subset of eight clones was chosen for follow-up (LaM 1-8; Supplementary Fig. 5 ). Codon-optimized genes for these hits were synthesized and cloned into a bacterial expression vector. After expression, we passed lysates over antigen-coupled resin to identify nanobodies that displayed robust expression as well as high and specific affinity ( Supplementary Fig. 6 ). From these screens, we found 25 specific nanobodies against GFP and 6 against mCherry. Phylogenetic analysis of the verified nanobodies revealed substantial sequence diversity among clones ( Supplementary Fig. 7) . Although our protocol is not directly analogous to phage display, the high success rate of this single screening step (57-75%) is favorable in comparison to the final panning and selection steps of phage display, in which up to 10 7 clones are screened to identify even a few positive clones 12, 14, 25, 26 . We assessed the affinity of the nanobodies further by either surface plasmon resonance (SPR) or in vitro binding assays with immobilized nanobodies (Supplementary Figs. 8-10 ). For the LaG repertoire these experiments revealed a wide range of affinities, with dissociation constants (K d ) from 0.5 nM to over 20 µM (Table 1) , and identified 16 nanobodies with high-affinity binding (≤50 nM; Supplementary  Fig. 8 ). The affinities of the six LaMs were consistently strong, with K d values ranging from 0.18 nM to 63 nM (Table 1 and Supplementary Fig. 9 ).
Diverse t arget antigens

specificity and efficacy of recombinant nanobodies
We performed a variety of experiments to assess our nanobodies. We first affinity-isolated endogenous GFP-and mCherry-tagged proteins in yeast and human cells. All 25 positive LaGs were used for the isolation of GFP-tagged Nup84, a structural nuclear-pore-complex npg component, in budding yeast 27, 28 (Fig. 2b) . We plotted each LaG's observed K d against a quantification of either signal-tobackground ratio or yield from a Nup84-GFP affinity capture (Fig. 2d,e and Table 1 ). Almost all LaGs pulled down detectable amounts of Nup84-GFP and its associated proteins, and many performed as well as or better than either our best affinity-purified polyclonal antibodies 1 or the single commercially available anti-GFP nanobody, GFP-Trap (ChromoTek), which has a K d of 0.59 nM ( Fig. 2b,g) 29 . For instance, when we determined depletion of Nup84-GFP by western blot, LaG-16 displayed slightly higher yields than GFP-Trap ( Supplementary Fig. 11 ).
Generally speaking, there were strong correlations between low K d and both high signal-to-background ratio and high yield, which is consistent with the relationship theoretically predicted for the percentage of low-abundance yeast target proteins bound in solution 30 (Fig. 2d) . Our ability to compare structurally similar nanobodies raised against a single antigen provided an opportunity to demonstrate the importance of very low K d to antibody performance in this type of application. Nanobodies showed a precipitous decline in affinity-purification performance as their K d values rose, even at values as low as 10 nM-typically considered high affinity for an antibody. These findings highlight the need for ultrahigh-affinity reagents, such as the nanobodies described here, for proteome and interactome studies.
We also performed affinity-capture experiments with GFPtagged RBM7, a component of the human nuclear exosome, from HeLa cells 4 (Fig. 2c) . We observed yields and purities comparable to those seen with Nup84-GFP. However, for certain LaGs, notably LaG-41, the amount of contaminants differed between purifications in yeast and purifications in HeLa cells (Fig. 2b,c) . These results underscore that even high-affinity reagents can produce unpredictable background in certain cell types. It is therefore useful to obtain and test large repertoires of such affinity reagents to improve the chances that at least one will be optimal for any particular application.
Similarly, we isolated mCherry-tagged histone H2B from yeast with LaMs conjugated to Dynabeads (Life Technologies; Fig. 2f ). All six LaMs efficiently isolated the core nucleosome complex, K d values for GFP and mCherry binding were determined by SPR unless otherwise noted. K d values are also listed for LaG dimers fused by a glycine-rich peptide linker (three repeats of GGGGS, or G 4 S) or by a 3×Flag linker. For yeast Nup84-GFP and mammalian RBM7-GFP affinity isolations using LaGs, Coomassie-stained bands from elutions separated by SDS-PAGE were quantified, and known specific and nonspecific bands were used to calculate signal-to-noise (S:N) ratios. Bead binding assays were used to determine affinity for fluorescent proteins, and the table highlights differences in specificity for A. macrodactyla CFP among LaGs and for DsRed among LaMs. GFP epitopes for LaGs were determined by NMR and classified into three groups according to their location (I-III). Also shown are the number of residues identified in the binding site and the site's calculated accessible surface area (ASA). MW, molecular weight; ND, not determined; N/A, not applicable. a K d determined by bead binding assay.
npg demonstrating the affinity and specificity of this second group of nanobodies. Consistent with the low K d values of all the identified LaMs, the yield and specificity of all affinity isolations were high. The commercial nanobody RFP-Trap (ChromoTek) was tested in parallel and had lower yields. Nanobodies are powerful new tools for fluorescence microscopy, both standard and super-resolution 31 . We therefore tested the effectiveness of selected members of the LaG and LaM repertoires for immunofluorescence microscopy ( Fig. 3 and Supplementary  Fig. 12 ). As target proteins, we first used Emerald GFP (EmGFP)tagged tubulin and mitochondria-targeted EmGFP, transiently transfected into HeLa cells 32 . We stained fixed cells with LaG-16 conjugated to Alexa Fluor 568 (Life Technologies), producing specific and strong staining of EmGFP-tagged microtubules or mitochondrial structures, with negligible nonspecific staining of untransfected cells (Fig. 3a,b) . To demonstrate the versatility of these reagents, we also used them for immunofluorescence in a Trypanosoma brucei strain with EGFP-tagged Sec13. This protein localizes to both the nuclear pore complex and COPIIcoated vesicles, and indeed, the Alexa Fluor 568-nanobody signal colocalized with EGFP to produce the expected staining of the nuclear rim and endoplasmic reticulum 33 (Fig. 3c) . To determine whether our anti-mCherry nanobodies were similarly well suited for immunofluorescence microscopy, we conjugated LaM-4 to Alexa Fluor 488 and stained Saccharomyces cerevisiae expressing mCherry-tagged H2B, resulting in specific, colocalized nuclear staining (Fig. 3d) .
As previous studies have demonstrated potentially useful modulation of GFP fluorescence activity by nanobodies 29 , we compared the fluorescence spectra of GFP in the presence or absence of various LaGs to look for spectral shifts upon binding. We observed moderate increases in fluorescence for several LaGs, with a maximum increase in fluorescence intensity of approximately 60% (Supplementary Fig. 13) .
One additional question of specificity we sought to address was the ability of our nanobodies to recognize other fluorescent homologs of Aequorea victoria GFP and Discosoma sp. mCherry. We tested the 13 highest-affinity LaGs against a variety of fluorescent proteins: EGFP, two yellow fluorescent protein variants, two cyan fluorescent protein variants, BFP, mCherry and DsRed (Fig. 4a) . None of these nanobodies bound DsRed or mCherry, two Discosoma-derived proteins with low sequence identity to EGFP (<30%), and none bound TurboYFP (Evrogen), derived from Phialidium sp., which has 53% sequence identity to EGFP 20, 34, 35 . All bound standard Aequorea victoria-derived CFP, YFP and BFP variants (>96% EGFP identity). Two LaGs did not bind a moderately divergent (78% EGFP identity) cyan fluorescent protein sequence from Aequorea macrodactyla, whereas all others did 36 . These results indicate that although the identified LaGs bind specifically to fluorescent proteins that have high identity to EGFP, differential binding activities can be obtained through use of variants from other species. Our anti-mCherry LaM nanobodies bound to mCherry but not to any of the green, yellow or cyan fluorescent proteins we tested (Fig. 4b) . Two LaMs (LaM-3 and LaM-4) bound to standard DsRed, which has approximately 80% sequence identity to mCherry. Given the different affinities of LaG and LaM nanobodies for fluorescent proteins, including variation in specificity for A. macrodactyla cyan fluorescent protein and DsRed, these reagents have diverse potential uses in differential labeling and affinity-capture experiments from cells simultaneously expressing multiple fluorescently tagged proteins.
mapping of the nanobody epitopes on GFP
We identified the epitopes on GFP recognized by the 12 highestaffinity LaGs using chemical shift perturbation, a well-established NMR technique. This method allows researchers to map binding sites on a protein by following changes in its characteristic 'fingerprint' spectrum (typically the 15 N-1 H HSQC spectrum) that result from adding an unlabeled ligand to a 15 N-labeled protein sample 37 .
Because previous studies have already made backbone 15 N-1 H chemical shift assignments for the GFPuv variant 38, 39 (closely related to standard EGFP, with 97% sequence identity), we prepared 15 N-labeled GFPuv, measured its 15 N-1 H HSQC spectrum and obtained chemical shift assignments on the basis of those published 38, 39 (Supplementary Fig. 14a ). We then tested complexes between 12 high-affinity LaGs and 15 Figs. 14b,c and 15 ). In the twelfth case, LaG-24, the nanobody did not bind the GFPuv variant.
A chemical shift difference was calculated for all spectra, and residues exhibiting a difference greater than 0.03 p.p.m. were judged to be in the binding interface ( Supplementary  Fig. 14b,c) 37, 40 . All the identified epitopes corresponded to large interfaces comprising more than 50 amino acids, consistent with the high-affinity binding we observed ( Fig. 5 and Table 1 ). The binding epitopes of the nanobodies can be divided into three distinct groups. The binding site of group I, containing five nanobodies (LaG-16, LaG-9, LaG-14, LaG-43 and LaG-17), overlaps with the binding site of group II, also containing five nanobodies (LaG-19, LaG-21, LaG-26, LaG-27 and LaG-41), whereas the group III nanobody (LaG-2) has a binding epitope on the opposite side of the GFP molecule. As a control, we also used this NMR approach to determine the GFPuv binding site of the commercial GFP-Trap nanobody, the structure of whose complex with GFP has been crystallographically determined (PDB 3K1K) 29 , and showed that the NMR-mapped epitope matched the published results 29, 41 (Supplementary Fig. 16 ). Comparing the binding epitopes of our nanobodies with that of GFP-Trap, groups I and II show little or no overlap with the GFP-Trap binding site, whereas group III, which binds on the same face of GFP, shows substantial overlap (Fig. 5) .
dimerized nanobodies as ultrahigh-affinity reagents
Because NMR identified multiple epitopes for these 12 LaGs, we engineered heterodimers of LaGs with nonoverlapping binding sites on GFP that could potentially bind with higher affinity, an approach that has been used successfully in various applications to develop high-avidity reagents 42, 43 . A LaG-16-LaG-2 fusion with a flexible glycine-rich peptide linker (encoding three repeats of GGGGS) had the highest affinity as measured by SPR, with a K d of 36 pM. Dimers of other LaGs and those with a different linker (a 3×Flag tag) displayed K d values in the range of 100-200 pM. We also sought to determine whether the higher affinity of these dimers yielded faster affinity isolations after conjugation Structural models were obtained from PDB 1EMA (Av) 52 , PDB 4HE4 (Phi) 53 and PDB 1GGX (Ds) 54 ; the Am CFP model is a Phyre server prediction 36, 55 . Gels are representative of at least two experiments. npg to magnetic beads, compared to single nanobodies or polyclonal anti-GFP. We therefore analyzed time courses of yeast Nup84-GFP isolations and compared the relative yields of known Nup84complex components. The LaG-16-LaG-2 dimer showed higher yields at earlier time points, reaching approximately 80% of maximum yield after only 5 min and 90% after 10 min ( Fig. 2g  and Supplementary Fig. 17) . These picomolar-affinity reagents open the door for increasingly rapid affinity isolations, potentially allowing the capture of weakly or transiently associated complex components for interactome studies. In addition, their high avidity would allow for the detection of low-abundance antigens, as is required for many diagnostic applications.
discussion
Our optimized pipeline for nanobody production allows for rapid generation of a large antibody repertoire against multiple epitopes in a chosen antigen. Notably, this approach identifies high-affinity nanobody sequences directly from animal serum, taking advantage of the complex selection and maturation processes occurring in the animal's immune system and avoiding intermediary expression systems. The pipeline can quickly produce a comprehensive repertoire of specific, high-affinity nanobodies for use in the characterization of target macromolecules, such as the GFP-and mCherry-tagged proteins used in this study. Only modest laboratory effort is required after the collection of samples from llamas (50-70 d after initial immunization, once an immune response is generated). The direct work required, including IgG purification (2 d), MS (2 d), cDNA generation and PCR (2 d), and final cloning and screening (3-6 d), can be performed over approximately 10 d. Animal handling, high-throughput sequencing, MS and gene synthesis can readily be outsourced, and depending on turnaround times, each can typically be carried out in 1-2 weeks. The entire process can take as little as 4-6 weeks after an immune response is generated, with only standard techniques required in the primary laboratory. This is faster and more direct than other approaches available, which often require specialized high-throughput capability. Our LaM and LaG reagents, generated against the widely used GFP and mCherry tags, will be of general use for the affinity isolation and enhanced visualization of these tags.
Our approach is well suited to the development of nanobody reagents against various types of protein targets, including proteins that are difficult to tag. The versatility and potential of nanobodies is huge, as reflected by the interest of the research community 8, 10, 44, 45 . Nanobodies are much smaller than antibodies, resist aggregation and can be readily 'humanized' 8, 46, 47 . They have great potential in drug development, as they can bind with great specificity and efficacy to disease targets such as tumor cells, either independently (as a monomer or an ultrahigh-affinity nanobody dimer) or as a fusion with other protein domains, molecules or drugs [48] [49] [50] [51] . Application of our method for nanobody generation has the potential to significantly advance a field that otherwise can take years to generate such reagents.
methods
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
online methods
Isolation of V H H antibodies.
For detailed information on the entire nanobody identification procedure, please see the Supplementary Protocol. In short, a 5 year old female llama (Lama glama), Barbie, was immunized with recombinant GFP-His 6 , and a 4 year old male llama, Marley, with recombinant mCherry-His 6 through subcutaneous injections of 5 mg of protein with CFA. Three additional injections of 5 mg protein with IFA were performed at three week intervals. Serum bleeds were obtained 10 days after the final injection. 2.5 ml of serum was diluted tenfold in 20 mM sodium phosphate, pH 7.0, and incubated with Protein G-agarose resin for 30 min. The flow-through was then incubated for 30 min with Protein A-agarose resin. Both resins were washed with 20 mM sodium phosphate, pH 7.0, and bound V H H IgG was eluted with 100 mM acetic acid, pH 4.0, and 500 mM NaCl (Protein G resin), or 100 mM acetic acid, pH 3.5, and 150 mM NaCl (Protein A resin). These elutions were pooled and dialyzed into PBS. 3 mg of this V H H fraction was then incubated with Sepharose-conjugated GFP. This resin was washed with 10 mM sodium phosphate, pH 7.4, and 500 mM NaCl, followed by 1-4. RT-PCR and DNA sequencing. Bone marrow aspirates were obtained from immunized llamas concurrent with serum bleeds. Bone marrow plasma cells were isolated on a Ficoll gradient using Ficoll-Paque (GE Healthcare). RNA was isolated from approximately 1 × 10 7 to 6 × 10 7 cells using Trizol LS reagent (Life Technologies), according to the manufacturer's instructions. cDNA was reverse-transcribed using Ambion RETROscript (Life Technologies). A nested PCR was then performed with IgG specific primers. In the first step, CALL001 (5′-GTCCTGGCTGCTCTTCTACAAGG-3′) and CALL002 (5′-GGTACGTGCTGTTGA ACTGTTCC-3′) primers were used to amplify the IgG variable domain into the CH2 domain 25 . The approximately 600-to 750-bp band from V H H variants lacking a CH1 domain was purified on an agarose gel. Next, for 454 sequencing, V H H regions were specifically reamplified using framework 1-and 4-specific primers with 5′ 454 adaptor sequences: 454-VHH-forward (5′-CGTATCGCCTCCCTCGCGCCATCAG ATGGCT[C/G]A[G/T]GTGCAGCTGGTGGAGTCTGG-3′) and 454-VHH-reverse (5′-CTATGCGCCTTGCCAGCCCGCT CAGGGAGACGGTGACCTGGGT-3′) (adaptor sequences are underlined) 25 . The approximately 400 bp product of this reaction was gel purified, then sequenced on a 454 GS FLX system after emPCR amplification, on one Pico Titer Plate. For Illumina MiSeq sequencing, the second PCR was instead performed with random 12-mers replacing adaptor sequences, to aid in cluster identification: MiSeq-VHH-forward (5′-NNNNNNNNNNNN
ATGGCT[C/G]A[G/T]GTGCAGCTGGTGGAGTCTGG-3′) and
MiSeq-VHH-reverse (5′-NNNNNNNNNNNN GGAGACGGTG ACCTGGGT-3′). The product of this PCR was gel purified, ligated to MiSeq adaptors before library preparation using Illumina kits, and run on a MiSeq sequencer with 2 × 300-bp paired-end reads.
Database preparation. The protein sequence databases used for identification were prepared by translating sequencing reads in all 6 reading frames, and for each read the longest open reading frame (ORF) was selected. The selected ORF was digested with trypsin in silico and a list of unique tryptic peptides of 7 amino acids or longer was constructed and saved in a FASTA file. It is important to construct a FASTA file only containing unique peptides because even though most search engines can handle some sequence redundancy, they are not well equipped to handle the extreme redundancy that is provided by next-generation sequencing of the single-chain antibody locus, and search engines either become very slow or crash if presented with such extreme redundancy.
Mass spectrometry. Gel sections containing V H H domains were excised, destained, and dehydrated. The dehydrated gel slices were then subjected to in-gel digestion with proteomic-grade trypsin (80 µL; 25 ng trypsin, 25 mM ammonium bicarbonate) (Promega) at 37 °C overnight. The gel was extracted once with extraction solution (140 µL; 67% acetonitrile, 1.7% formic acid). The resulting proteolytic digest was cleaned with a STAGE tip 56 and loaded onto a home-packed reverse phase C18 column (75 µm I.D., 15 µm tip) (New Objective) with a pressurized bomb. The loaded peptides were subsequently separated with a linear gradient (0% to 42% acetonitrile, 0.5% acetic acid, 120 min, 150 nL/min after flow splitting) generated by an Agilent 1260 HPLC and directly sprayed into an LTQ-Velos-Orbitrap mass spectrometer (Thermo Scientific) for analysis. In the mass spectrometer, a survey scan was carried out in the orbitrap (resolution = 30,000, AGC target = 1E6) followed by tandem MS in the ion trap (AGC target = 5E3) of the top twenty most intense peaks. Tandem MS was carried out with collision-induced dissociation (isolation width = 2 Th, CE = 35%, activation time = 5 ms). Internal calibration was used for improved mass accuracy (lock mass m/z = 371.1012). In order to scan more peptides, both predictive AGC and dynamic exclusion were enabled (repeat counts: 2, repeat duration: 12 s, exclusion duration: 60 s). Single and unassigned charge species were excluded from tandem MS scans. The raw files were converted into mzXML format with ReAdW (version 4.3.1).
MS-based identification of V H H sequences.
The MS search was performed on the custom database of tryptic peptides using the X! Tandem search engine. Then the identified peptides, filtered by expectation value, were mapped to the sequences translated from DNA sequencing reads (longest ORF only, as described above). The CDR regions were located within the sequence on the basis of approximate position in the sequence and the presence of specific leading and trailing amino acids. For example, to locate the CDR3 region, the algorithm searched for the left anchor YXC (X representing any amino acid) between position 93 and 103 of the sequence, and the right anchor WG between position n -14 and n -4 of the sequence, where n is the length of the sequence. Once the peptides were mapped to the sequences and their CDR regions, a metric was calculated to rank each sequence as a potential candidate on the basis of the bioinformatics evidence available. The factors included in the metric were: MS coverage and length of individual CDR regions, with CDR3 carrying highest weight; overall coverage including framework region; and a count of the reads producing the sequence. Finally, sequences with similar CDR3 regions were grouped together, allowing for the identification of the highest-confidence sequence corresponding to a particular CDR3. A sequence was assigned to a group where its hamming distance to an existing member was 1, i.e., there was one amino acid difference in the sequence, and different groups that have one shared sequence were further combined. By choosing sequence hits from different groups for production, we maximized the overall sequence diversity of the candidate pool. The candidate list was displayed for manual inspection as an interactive HTML page with CDR regions annotated and peptide mapping information and the ranking metrics shown for each sequence. All algorithms described above were implemented in Perl. An example of a candidate list view is shown in Supplementary Figure 3 .
Web-based application for nanobody sequence identification: 'Llama Magic' . The pipeline that was used for identification of the nanobody sequences has been automated and can be accessed through a web-based interface at http://www.llamamagic.org/. Source code is available at https://github.com/FenyoLab/llamamagic. Llama Magic allows upload of FASTA files containing reads from high-throughput DNA sequencing. Once uploaded, the reads will be automatically translated and digested to create an MS-searchable database of tryptic peptides, as described above. Next, the MS (MGF) files can be uploaded for a selected tryptic peptide sequence database, and the parent and fragment error can be chosen for the X! Tandem search. Once the MGF files are uploaded, the X! Tandem search will be executed and the matching peptides saved. Then (i) annotation of CDR regions, (ii) mapping of the identified peptides and (iii) ranking and grouping of candidates are performed automatically, producing an interactive display of the candidate list showing detailed information regarding each sequence and its corresponding rank. Llama Magic is implemented in Perl, HTML and JavaScript. Manual inspection was performed to make sure (i) long CDR3 peptides, which embrace both variable regions and framework regions, have fragmentation pattern within the variable regions; (ii) CDR3 peptides are unique enough (uniqueness score <100).
Cloning. Nanobody sequences were codon-optimized for expression in Escherichia coli and cloned into pCR2.1 after gene synthesis (Eurofins MWG Operon), incorporating BamHI and XhoI restriction sites at 5′ and 3′ ends, respectively. A pelB leader sequence was cloned into pET21b at NdeI and BamHI restriction sites using complementary primers: 5′-TATGAAATACTTATTG CCTACGGCAGCCGCTGGATTGTTATTACTCGCGGCCCAG CCGGCCATGGCTG-3′ and 5′-GATCCAGCCATGGCCGGCTG GGCCGCGAGTAATAACAATCCAGCGGCTGCCGTAGGCAA TAAGTATTTCA-3′. Nanobody sequences were then subcloned into pET21b-pelB using BamHI and XhoI restriction sites, with primers also encoding a PreScission Protease (GE Healthcare) cleavage site just before the C-terminal His 6 tag.
All chemical shift differences were calculated using equation (1) where CSD is the total chemical shift difference and ∆δN and ∆δH are the chemical shift differences in the free and bound states between the amide nitrogens and protons, respectively. The CSD cutoff for binding-site residues was 0.05 p.p.m. for GFP-Trap binding site and for GFPuv dimerization site and 0.03 p.p.m. for all LaG binding sites. All LaG binding-site residues are listed in Supplementary  Table 2 , and their respective 1 H-15 N HSQC spectra are shown (1) (1) in Supplementary Figure 15 overlaid with the 1 H-15 N HSQC spectrum of the free GFPuv_M.
